You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
春立医疗(01858.HK)中期纯利升116.62%至1.09亿元
格隆汇 08-27 21:55

格隆汇8月27日丨春立医疗(01858.HK)公布,截至2019年6月30日止中期,公司实现营业收入人民币3.75亿元(单位下同),同比增长75.93%;归属于公司权益持有人的净利润1.09亿元,同比增长116.62%;每股基本收益0.79元。营业收入增长主要是由于关节假体产品销量的增长及销售网络的扩张所致。

关节假体产品于截至2018年6月30日的约2.10亿元增长76.3%至3.69亿元,其中陶瓷关节假体产品、XN系列膝关节假体产品及微创髋关节假体产品等主流高端产品在行业增长迅速。随着公司的陶瓷关节假体产品在各省的招标、补标或医院备案等逐渐进行,2019年陶瓷关节假体产品销量占产品组合比重快速增长。

此外,公司为国内首家且唯一一家引进有关DAMIS及欧洲先进微创技术的企业,并大力推广及使用DAMIS产品及技术,带动了微创相关产品的销量。

公司的研发费用由2018年同期的约900万元上升至2580万元,公司的2019年上半年研发费用占收入的比例为6.88%。主要是由于研发人员增加,委聘国内外专家通过临床测试改良公司的中国国民骨骼数据库,研发符合国人生理情况的新产品;同时加强了新产品样品试制、产品的疲劳、磨损性能测试以及模拟临床应用的测试。保证了产品的安全性、有效性。同时临床试验和、产品注册等方面取得了重大进展。多项高端新产品临床试验已进入随访期,同时,多项新产品注册进入发补后审评阶段。

截至2019年06月30日,公司已取得60项专利,并已申请48项新专利。截至2019年6月30日,公司获得的创新医疗器械特别审批项目《单髁膝关节假体》(受理号:CQTS1700268)已进入临床随访阶段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account